These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26560746)

  • 21. Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
    Tran DQ; Harvey RD; Meeks SL; Chapman R; Kempton CL
    Haemophilia; 2014 Jul; 20(4):e344-6. PubMed ID: 24750497
    [No Abstract]   [Full Text] [Related]  

  • 22. Massive factor-VIII infusion in Haemophiliac with factor-VIII inhibitor, high responder. 1977.
    Brackmann HH; Gormsen J
    Haemophilia; 2010 May; 16(102):2-3. PubMed ID: 20536980
    [No Abstract]   [Full Text] [Related]  

  • 23. Haemophilia.
    Jones P
    Physiotherapy; 1976 Jun; 62(7):214-6. PubMed ID: 967940
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful liver surgery in a haemophilia patient with high titre factor VIII inhibitor.
    Jones AE; Roy A; Armstrong T; Rees M; Welsh FK
    Haemophilia; 2009 Nov; 15(6):1332-3. PubMed ID: 19624759
    [No Abstract]   [Full Text] [Related]  

  • 25. The impairment in daily life of obese haemophiliacs.
    Biere-Rafi S; Haak BW; Peters M; Gerdes VE; Büller HR; Kamphuisen PW
    Haemophilia; 2011 Mar; 17(2):204-8. PubMed ID: 21332881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.
    Kremer Hovinga ICL; Schutgens REG; van der Valk PR; van Vulpen LFD; Mauser-Bunschoten EP; Fischer K
    Haemophilia; 2018 Jul; 24(4):e280-e283. PubMed ID: 30044044
    [No Abstract]   [Full Text] [Related]  

  • 27. Central venous access device insertion and perioperative management of patients with severe haemophilia A: a local experience.
    Fonseca A; Nagel K; Decker K; Pukulakatt M; Pai M; Walton M; Chan AK
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):156-9. PubMed ID: 26340458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orthopaedic outcome of total knee replacement in haemophilia A.
    Cohen I; Heim M; Martinowitz U; Chechick A
    Haemophilia; 2000 Mar; 6(2):104-9. PubMed ID: 10781197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose pharmacokinetics of porcine factor VIII (Hyate C).
    Hermans C; Owens D; Longo G; Morfini M; Lee CA
    Thromb Haemost; 2002 Feb; 87(2):352-3. PubMed ID: 11858504
    [No Abstract]   [Full Text] [Related]  

  • 32. Coronary artery bypass surgery in a patient with Haemophilia A: a case report.
    Menard CE; Zawadski D; Singal RK; Rimmer E; Houston DS; Houston BL; Zarychanski R
    Haemophilia; 2016 Jan; 22(1):e76-9. PubMed ID: 26635300
    [No Abstract]   [Full Text] [Related]  

  • 33. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.
    Nilsson IM; Hedner U; Holmberg L
    Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094
    [No Abstract]   [Full Text] [Related]  

  • 34. [Changes in coagulation factor VIII after liver transplantation in a patient with hemophilia A].
    Deshayes JP; Tartière J; Samba D; Auvray S; Segol P; Lequerrec A; Derlon A
    Presse Med; 1992 Feb; 21(5):216. PubMed ID: 1532088
    [No Abstract]   [Full Text] [Related]  

  • 35. Extended half-life factor VIII for immune tolerance induction in haemophilia.
    Malec LM; Journeycake J; Ragni MV
    Haemophilia; 2016 Nov; 22(6):e552-e554. PubMed ID: 27640873
    [No Abstract]   [Full Text] [Related]  

  • 36. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose of non-heat-treated factor VIII concentrate and HIV-1 RNA levels.
    Montoro JB; Oliveras J; Altisent C; Ruiz I
    JAMA; 1997 Jan; 277(1):20-1. PubMed ID: 8980200
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of hemophilia with factor VIII concentrates.
    Agarwal MB; Mehta BC
    Indian J Med Sci; 1980 Sep; 34(9):226-30. PubMed ID: 6782019
    [No Abstract]   [Full Text] [Related]  

  • 40. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE; Bona RD; Rickles FR
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.